Cargando…

Thromboprophylaxis Strategies for Hospitalized Patients With COVID-19

Detalles Bibliográficos
Autores principales:	Porres-Aguilar, Mateo, Mukherjee, Debabrata, Lazo-Langner, Alejandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Chest Physicians. Published by Elsevier Inc. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257159/ https://www.ncbi.nlm.nih.gov/pubmed/35809961 http://dx.doi.org/10.1016/j.chest.2022.03.038

Ejemplares similares

Thromboprophylaxis strategies for COVID-19 patients
por: Porres-Aguilar, Mateo, et al.
Publicado: (2022)

ThromboprophylaXIs with Factor XI/XIa inhibitors for venous thromboembolism
por: Porres-Aguilar, Mateo
Publicado: (2023)

COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis
por: Porres-Aguilar, Mateo, et al.
Publicado: (2021)

Anticoagulation strategies and outcomes during extracorporeal membrane oxygenation support: a single-centre pre-COVID-19 experience
por: Nepomuceno, Roman, et al.
Publicado: (2023)

Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor?
por: Dutt, Tina, et al.
Publicado: (2020)

Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis
por: Mehta, Puja, et al.
Publicado: (2021)

May–Thurner Syndrome in Pregnancy-Associated Venous Thromboembolism
por: Porres-Aguilar, Mateo, et al.
Publicado: (2021)

Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions
por: Porres‐Aguilar, Mateo, et al.
Publicado: (2019)

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Rappaport, Stephen H., et al.
Publicado: (2020)

Pulmonary embolism response teams in the challenging era of venous thromboembolism associated with COVID-19
por: Porres-Aguilar, Mateo, et al.
Publicado: (2020)

Thromboprophylaxis for venous thromboembolism prevention in hip fracture patients
Publicado: (2017)

Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Dutt, Tina, et al.
Publicado: (2020)

Thromboprophylaxis strategies to improve the prognosis of COVID-19
por: Bertoletti, Laurent, et al.
Publicado: (2021)

Hospital-based use of thromboprophylaxis in patients with COVID-19
por: Spyropoulos, Alex C, et al.
Publicado: (2020)

Management of perioperative thromboprophylaxis for surgery following COVID-19: an expert-panel survey
por: Ferrandis, Raquel, et al.
Publicado: (2021)

High Flow Nasal Cannula Oxygenation Successfully Used as Bridge Therapy for Systemic Thrombolysis in COVID-19 Associated Intermediate-high Risk Pulmonary Embolism
por: Aguilar-Piedras, María F., et al.
Publicado: (2022)

The Role of D-Dimer for Optimal Thromboprophylaxis Strategy in Patients with COVID-19
por: Bhoopat, Lantarima, et al.
Publicado: (2020)

Thromboprophylaxis for children hospitalized with COVID‐19 and MIS‐C
por: Schmitz, Anna H., et al.
Publicado: (2022)

Thromboprophylaxis in Patients With Cancer and COVID-19
por: Lecumberri, Ramón, et al.
Publicado: (2022)

Extended Thromboprophylaxis in Patients with COVID-19
por: Zhao, Wei, et al.
Publicado: (2021)

Renal function in the ICU: always look both ways before initiating venous thromboprophylaxis
por: Baptista, João Pedro, et al.
Publicado: (2023)

The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute the simple solution. Author's reply
por: Hofmaenner, Daniel A., et al.
Publicado: (2022)

Venous Thromboembolism in Hospitalized Critical and Noncritical COVID-19 Patients: A Systematic Review and Meta-analysis
por: Mansory, Eman M., et al.
Publicado: (2021)

Incidence of Venous Thromboembolism in Hospitalized COVID-19 Patients Receiving Thromboprophylaxis
por: Huang, Jimmy, et al.
Publicado: (2022)

COVID-19 and Elevated D-Dimer: A Tale of Caution
por: Auron, Moises, et al.
Publicado: (2022)

WITHDRAWN: A dynamic, D-dimer-based thromboprophylaxis strategy in patients with COVID-19
por: Bhoopat, Lantarima, et al.
Publicado: (2021)

Stroke and Thromboprophylaxis in the Era of COVID-19
por: Ma, Alice, et al.
Publicado: (2021)

Coagulation abnormalities & thromboprophylaxis in COVID-19
por: Jandial, Aditya, et al.
Publicado: (2021)

Thromboprophylaxis in COVID-19 – Rationale and considerations
por: Bristogiannis, Sotirios, et al.
Publicado: (2021)

Integral assays of hemostasis in hospitalized patients with COVID-19 on admission and during heparin thromboprophylaxis
por: Bulanov, Andrey Y., et al.
Publicado: (2023)

Letter to Editor: Strategy for Hospitalization and Discharge of COVID-19 Patients: Based on the Nationwide Clinical Course Analysis
por: Kim, Yeonjae, et al.
Publicado: (2020)

Nutritional strategies for the rehabilitation of COVID-19 patients
por: Azzolino, Domenico, et al.
Publicado: (2020)

Pharmacologic therapeutic options for thromboprophylaxis in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy
por: Daughety, Molly, et al.
Publicado: (2020)

Response to: Nutritional strategies for the rehabilitation of COVID-19 patients
por: Brugliera, Luigia, et al.
Publicado: (2020)

Management of diabetes in patients with COVID-19
por: Mukherjee, Jagat J, et al.
Publicado: (2020)

Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?
por: Iba, Toshiaki, et al.
Publicado: (2021)

Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
por: Jonmarker, Sandra, et al.
Publicado: (2020)

Enhanced thromboprophylaxis in critically ill patients with COVID-19 infection
por: Kummer, R.L., et al.
Publicado: (2021)

Intensified thromboprophylaxis in COVID-19 critically ill patients: Is it enough?
por: de Montmollin, Etienne, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5fbh8ho0khhp5sosl4lh3n5iqb